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The pathogenesis of Crohn’s disease (CD) involves defects in the innate immune system, impairing responses to microbes. Studies
have revealed that mutations NLRP3 are associated with CD. We reported previously that Nlrp3−/−mice were more susceptible to
colitis and exhibited reduced colonic IL-10 expression. In the current study, we sought to determine how the loss of NLRP3 might
be altering the function of regulatory T cells, a major source of IL-10. Colitis was induced in wild-type (WT) and Nlrp3−/−mice by
treatment with dextran sulphate sodium (DSS). Lamina propria (LP) cells were assessed by flow cytometry and cytokine expression
was assessed. DSS-treated Nlrp3−/−mice exhibited increased numbers of colonic foxp3+ T cells that expressed significantly lower
levels of IL-10 but increased IL-17.This was associated with increased expression of colonic IL-15 and increased surface expression of
IL-15 on LP dendritic cells. Neutralizing IL-15 in Nlrp3−/−mice attenuated the severity of colitis, decreased the number of colonic
foxp3+ cells, and reduced the colonic expression of IL-12p40 and IL-17. These data suggest that the NLRP3 inflammasome can
regulate intestinal inflammation through noncanonical mechanisms, providing additional insight as to how NLRP3 variants may
contribute to the pathogenesis of CD.
1. Introduction
The pathogenesis of the inflammatory bowel disease (IBD),
Crohn’s disease (CD), and ulcerative colitis (UC) is unknown;
however the current paradigm suggests that aberrant imm-
une interactions between genetically susceptible individuals
and environmental factors trigger the chronic inflammatory
response [1]. Although it is apparent that, through dysreg-
ulated T cell function, the adaptive immune system drives
chronic inflammation in IBD, it has been hypothesized that
deficiencies in the innate immune system that render it
hyporesponsive to the intestinal microbiota also play a role
in the initiation of the inflammatory response [2]. Indeed,
genome-wide association studies have reported that loss-of-
functionmutations in the genes encodingmicrobial receptors
of the innate immune system, such as NOD2 and NLRP3
(nucleotide-binding, leucine-rich repeat (NLR) family, pyrin
domain containing 3), are associated with an increased risk
for CD [3, 4].
NLRP3, a member of the NLR subfamily of innate
immune receptors and component of the inflammasome, is
involved in the caspase-1-dependent processing of pro-IL-1𝛽
and pro-IL-18 in response to a variety of pathogens and endo-
genous danger signals [5]. In a previous study, we reported
that Nlrp3−/− mice were more susceptible in experimental
models of colitis [6], exhibiting decreased intestinal barrier
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function, altered expression of antimicrobial peptides, and
a unique intestinal microbiota. Others have reported that
the NLRP3 inflammasome is integral in the maintenance of
mucosal integrity through its processing of pro-IL-18 [7, 8].
More recently, the NLRP6 inflammasome, whose activating
ligands have yet to be identified, has been implicated as a
regulator of intestinal mucosal homeostasis by shaping the
intestinal microbiota and enhancing mucosal regeneration
following colitis-associated injury [9–12]. Taken together
these data highlight the importance of inflammasomes in the
regulation of intestinal homeostasis.
In addition to the broad changes in innate mucosal imm-
une function, our previous report indicated that Nlrp3−/−
mice exhibited reduced colonic IL-10 and TGF-𝛽, suggesting
that alterations in inflammasome function may trigger pro-
found changes in the function of additional cell types, such
as T cells [6]. Interestingly, T cell-inflammasome interactions
have been reported in a number of different organ systems.
Interferon-𝛽-primed memory T cells can inhibit inflamma-
some signaling in monocytes by downregulating the P2X
7
receptor [13], whereas T cell-derived IL-22 enhances inflam-
masome activation in adipose-derived macrophages [14]. On
the other hand, inflammasomes have been implicated in
the regulation of T cell function, enhancing T helper type-1
(Th1) and T helper type-17 (Th17) responses in experimental
autoimmune encephalomyelitis [15]. Furthermore, NLRP3
activation has been associated with the mechanisms that
drive T helper type-2 (Th2) responses and allergic sensitiza-
tion in the airways [16]. Taken together, it is apparent that
there is a complex interplay between inflammasome signaling
and T cells, suggesting reciprocal modulation of function.
In the gastrointestinal tract, T cell dysregulation is associ-
ated with enhanced mucosal inflammation. In animal mod-
els, deletion of IL-10, a prototypical T regulatory cell- (Treg-)
derived immunomodulatory cytokine, results in spontaneous
intestinal inflammation [17]. In human IBD, Th17 cells are
thought to contribute to intestinal inflammation as the
expression of IL-17 is significantly elevated in the inflamed
mucosa of CD patients [18]. Furthermore, other reports
suggest a disruption in the delicate equilibrium between Treg
populations andTh17 cells in themucosa of IBD patients [19].
Additionally, polymorphisms in the gene encoding the recep-
tor for IL-23, a cytokine that is critical in the development of
the Th17 lineage, are associated with a number of inflamma-
tory disorders, including IBD [20, 21].
Given the conclusions from the aforementioned studies,
and the data from our previous report indicating that the
deletion of Nlrp3 was associated with reduced colonic IL-10
and more severe colitis, in the current study we sought to test
the hypothesis that the NLRP3 inflammasome contributes to
the maintenance of intestinal homeostasis through its ability
to regulate Treg cell function. Herein we report that colitic
Nlrp3−/− mice exhibit increased numbers of foxp3+ Treg
cells in the colonicmucosa, but these cells display reduced IL-
10 expression compared to cells isolated fromwild-type (WT)
mice. Furthermore, foxp3+ Treg cells isolated from colitic
Nlrp3−/−mice display enhanced plasticity towardsTh17with
increased expression of IL-17. Nlrp3−/− dendritic cells (DCs)
exhibit enhanced expression of IL-15, a cytokine reported
to drive foxp3+ cell proliferation while inhibiting Treg cell
function [22, 23]. Lastly, inhibition of IL-15 signaling with
a neutralizing antibody protected Nlrp3−/− from colitis, an
effect that was associated with a reduction in the expression
of IL-17 in colonic tissue.
2. Methods
2.1. Animals. All experiments were approved by the Health
Sciences Animal Care Committee, University of Calgary, and
conform to the guidelines set by the Canadian Council on
Animal Care. Wild-type (WT) and Nlrp3−/− (both on a
C57Bl/6 background) mice were generated from Nlrp3+/−
mice (a gift from the lateDr. Tschopp,University of Lausanne,
Dorigny, Switzerland) andmales used between 8 and 10weeks
of age.
2.2. Induction and Assessment of Colitis. Colitis was induced
by the addition of dextran sulphate sodium (DSS; 3.5% w/v,
molecular weight, 40,000; ICNBiomedical; Solon, OH, USA)
to the drinking water as described previously [6]. Animals
were assessed and body weights recorded daily. Hematocrit
values were assessed as an index of blood loss. Tissue damage
was assessed in a blinded fashion using parameters that we
have described previously [6].
2.3. Assessment of Tissue Myeloperoxidase Activity and Cytok-
ine Levels. Myeloperoxidase (MPO) activity was determined
following a published protocol [24]. MPO activity was
reported as units/mg tissue, where one unit of MPO was
defined as the amount of enzyme needed to degrade 1 𝜇mol of
H
2
O
2
per minute at room temperature. Cytokine levels were
assessed with a Luminex XMap bead-based cytokine array as
we have described previously [6]. Colonic segments stored
at −80∘C were placed in ice-cold lysis buffer (250 𝜇L/25mg
tissue; 10mM Tris pH 7.5, 1% NP-40, 150mMNaCl, and pro-
tease inhibitor cocktail), minced with dissection scissors and
then homogenized, decanted into sterile Eppendorf tubes,
and centrifuged at 12,000 rpm for 15minutes.The supernatant
was then filtered through an Ultrafree-MC centrifugal filter
device (Millipore Corp.) with centrifugation at 12,000 rpm
for 5 minutes. The protein concentration of all samples was
equalized by dilution with lysis buffer. To assess cytokine
levels, prelabeled beads were mixed and added to each well
along with samples prepared in triplicate at two different total
protein concentrations (10 and 35mg total protein). Samples
were incubated with beads for 2 hours and then washed 3
times and incubated with secondary antibodies for 1 hour.
Following incubation, wells were washed and then beads
assessed in the Luminex 200 System. Mean fluorescence
valuesweremeasured and cytokine concentrations calculated
using the prepared standards.
2.4. Immunofluorescent Staining for foxp3 and IL-15. Paraffin
embedded tissue was stained as described previously [25].
Sections were incubated with anti-mouse foxp3 (BioLegend
Cat.# 320001; San Diego, CA, USA) or biotin-conjugated
anti-mouse IL-15 (R&D Systems Cat.# BAF 447; Burlington,
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ON, CAN). Cell counts were performed in a blinded fashion
under fluorescent microscopy and expressed as the number
of positive cells per high-powered field (HPF; 40x).
2.5. Neutralizing Anti-IL-15 Antibody Treatment. Nlrp3−/−
mice were treated daily with a neutralizing anti-IL-15 anti-
body or rat IgG isotype control antibody (eBioscience, 5𝜇g
i.p. daily in 100 𝜇L of sterile saline; San Diego, CA, USA)
as described by Watkins et al. [26], starting one day before
DSS exposure. Colitis severity was assessed as described
previously [6].
2.6. Flow Cytometric Analysis of Freshly Isolated Lamina
Propria Cells and Splenocytes. To assess dendritic cell and
T cell subsets, leukocytes were extracted from the lamina
propria (LP) of the colon as previously described [25].
Splenocytes were isolated with mechanical disruption by
macerating the spleen through a 100𝜇m cell sieve. Isolated
cells were washed with Stabilization Buffer (PBS containing
0.2% (w/v) BSA and 0.1% (w/v) sodium azide) followed by
centrifugation (1000 rpm, 10 minutes). After blocking with
CD32/CD16 antibodies (clone 2.4GK, BD Biosciences; San
Diego, CA, USA), cells were labeled with anti-mouse CD3
(clone 17A2) and CD4 (clone GK1.5) and foxp3 (clone FJK-
16s) antibodies (eBioscience; San Diego, CA, USA). Intracel-
lular foxp3 expression was detected using the Foxp3 Stain Kit
(eBioscience; San Diego, CA, USA) as per the manufacturer’s
protocol. DCs were stained with anti-mouse CD11c (clone
HL3), CD45R/B220 (clone RA3-6B2), I-A/I-E (class II MHC,
clone 2G9), CD8a (clone 53-6.7), and CD11b (clone M1/70)
antibodies (all from BD Biosciences Pharmingen; Missis-
sauga, ON, CAN). Our gating strategy for DC experiments
is as follows: first, a side scatter low DC/macrophage gate was
employed. Next, DCs were defined as the CD11c and I-A/I-
E expressing population. DC subsets were characterized by
further gating to define plasmacytoid DC as B220 high and
CD11b low; myeloid DC as B220 negative and CD11b high;
and lymphoid DC as CD8a expressing populations.
2.7. Flow Cytometric Assessment of Intracellular Cytokines. To
detect intracellular cytokine expression, isolated splenocytes
as well as LP cells were cultured with phorbol 12-myristate
13-acetate (PMA, 5 ng/mL, Sigma-Aldrich; Oakville, ON,
CAN) and ionomycin (15 nM, Sigma-Aldrich; Sigma-Aldrich;
Oakville, ON, CAN) for 1 hour followed by incubation with
Golgistop (Monensin, BD Biosciences; San Diego, CA, USA)
for 12 hours (5% CO
2
and 95% humidity at 37∘C). Surface
staining was performed with CD4 and CD25 (clone PC61,
BD Biosciences; San Diego, CA, USA) antibody, followed
by a wash in Stabilization Buffer. Intracellular cytokine
staining was performed using the Cytofix/Cytoperm Kit (BD
Biosciences; San Diego, CA, USA) as per the manufacturer’s
protocol. The following primary antibodies were used: fluo-
roconjugated rat IgG1 anti-mouse IL-10 (clone JES5-16E3; BD
Biosciences; San Diego, CA, USA) and IL-17A (clone TC11-
18H10; BD Biosciences; San Diego, CA, USA).
2.8. Generation of BoneMarrow-DerivedDCs. Briefly, femurs
and tibias of themice were dissected, and themarrow flushed
with complete RPMI media. The bone marrow (BM) cells
were pelleted by centrifugation (1300 rpm, 6 minutes) at 4∘C
and then plated on to noncoated Petri dishes for 10 days at a
concentration of 108 cells/dish with recombinant mouse Flt3
ligand (Flt3L, 100 ng/mL, eBioscience). The Flt3L-containing
media was changed every 3 days.
2.9. Statistics. All values are represented as the mean ±
standard error of the mean (SEM). Simple, two-group com-
parisons were analyzed using Student’s 𝑡-test. For multiple
comparisons, a two-way ANOVA was utilized followed by a
Newman-Keuls post hoc test.
3. Results
3.1. Nlrp3−/− Mice Exhibit Increased Susceptibility to Exper-
imental Colitis, an Effect Associated with Reduced IL-10
Expression but Increased Numbers of Colonic foxp3+/CD4+
Cells. Over the 7-day course of DSS treatment, Nlrp3−/−
mice exhibited significantly greater weight loss (Figure 1(a))
and increased colonic MPO levels (assessed on day 7 of DSS;
Figure 1(b)), indicating enhanced granulocytic inflammatory
infiltration. In our previous characterization of the Nlrp3−/−
mice, we reported that these mice exhibited reduced colonic
IL-10 expression during the inflammatory phase of DSS-
induced colitis [6]. To determine whether the loss of NLRP3
inflammasome function and the resulting increased suscep-
tibility to experimental colitis were driven by changes in T
cell phenotype, we assessed the expression of IL-10 in CD4+
and CD8+ T cell populations isolated from the colonic LP.
Interestingly, we observed reduced IL-10 expression inCD4+,
but not CD8+ T cells isolated from Nlrp3−/− mice on day
7 of DSS when compared to those isolated from WT mice
(Figure 1(c)). There were no differences in total CD4+/CD3+
or CD8+/CD3+ cells between colitic WT and Nlrp3−/−mice
(Figures 1(d) and 1(e)).
Given the dramatic reduction in IL-10 expression in the
CD4+ cells isolated from Nlrp3−/−mice, we sought to assess
the number of foxp3+/CD4+ cells in the colonic tissues
from DSS-exposed WT and Nlrp3−/− mice. Interestingly,
despite decreased IL-10 expression in colitic Nlrp3−/− mice,
we observed a significant increase in the number of foxp3+
cells in the colonic mucosa of Nlrp3−/− mice following a 7-
day course of DSS (Figures 2(a) and 2(b), quantified in 2(c)).
This was confirmed with flow cytometric analysis of LP cells
(foxp3+/CD4+ cells) isolated fromWT and Nlrp3−/− on day
7 of DSS (Figure 2(d)).
3.2. DSS-TreatedNlrp3−/−MiceDisplay Reductions in foxp3+/
IL-10 Cells but an Increase in Number of foxp3+/IL-17 Cells.
Since we observed a paradoxical increase in the number of
foxp3+ cells in Nlrp3−/− mice, despite reduced colonic/
foxp3+ cell IL-10 expression, we next sought to deter-
mine whether the foxp3+/CD4+ cells isolated from colitic
Nlrp3−/− exhibit alterations in cytokine expression. Flow
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Figure 1: Nlrp3−/−mice exhibit enhanced susceptibility to DSS-induced colitis, a phenotype that associated with reduced IL-10 expression.
(a) Changes in body weight during a 7-day course of DSS (3.5% w/v in drinking water) in WT and Nlrp3−/− mice. ∗ denotes 𝑝 < 0.05
compared to WT; 𝑛 = 6/group. (b) Colonic tissue myeloperoxidase (MPO) levels assessed in WT and Nlrp3−/− mice on day 7 of DSS. ∗
denotes 𝑝 < 0.05 compared to WT mice; 𝑛 = 6/group. (c) Flow cytometric analysis of IL-10 expression in CD4+ and CD8+ T cells from the
LP of WT and Nlrp3−/−mice on day 7 of DSS. ∗ denotes 𝑝 < 0.05 compared to WTmice; 𝑛 = 6/group. (d) Flow cytometric analysis of total
CD4+/CD3+ and (e) CD8+/CD4+ cells isolated from the LP of WT and Nlrp3−/−mice on day 7 of DSS; 𝑛 = 6/group.
cytometric analysis of foxp3+/CD4+ cells isolated fromDSS-
treated Nlrp3−/− mice revealed reduced IL-10 expression in
the Nlrp3−/− cells, compared to WT (Figure 2(e)). Further
assessment of the foxp3+/CD4+ population of cells revealed
a significant increase in the expression of IL-17 in cells
isolated from DSS-exposed Nlrp3−/− mice, compared to
those isolated fromWTmice (Figure 2(f)), an effect that was
not evident in naive, non-DSS-treatedmice. No differences in
IL-17 expressionwere observed in foxp3−/CD4+ cells isolated
from DSS-treated Nlrp3−/− and WT mice (Figure 2(g)).
3.3. Nlrp3−/− Mice Exhibit Enhanced IL-15 Expression.
Recent reports have highlighted the existence of foxp3+/IL-
17+ cells in the tissue [27] and peripheral blood [28] of
patients with IBD. Furthermore, Ferretti et al. reported that
foxp3+ cells could be driven to increase the expression of
IL-17 through the action of IL-15 [29]. Thus, we sought
to determine if the aberrant cytokine expression observed
in foxp3+ cells isolated from colonic tissue of DSS-treated
Nlrp3−/− mice could be driven by increased expression
of IL-15. Indeed, DSS-treated Nlrp3−/− displayed enhanced
colonic IL-15 expression when assessed by a Luminex bead-
based assay (Figure 3(a)), an observation that was confirmed
by immunostaining colonic sections for IL-15 (Figures 3(b)
and 3(c)). Previous reports have suggested that DCs are a
significant source of IL-15 in intestinal tissue [30]. Expressed
on the surface of DCs, IL-15 canmodulate T cell function and
can trigger the proliferation of foxp3+ T cells [30–32]. Thus,
we sought to assess the expression of IL-15 on DCs isolated
from the colonic LP of DSS-treated mice. Interestingly, we
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Figure 2: DSS-treated Nlrp3−/− mice exhibit increased numbers of colonic foxp3+ cells that exhibit reduced IL-10 but increased IL-17
expression. Representative images of (a) WT and (b) Nlrp3−/− colonic sections stained for foxp3; scale bar = 50 microns. (c) Quantification
of foxp3+ cells in WT versus Nlrp3−/− mice on following 7 days of DSS exposure. Data are expressed as the number of foxp3+ cells per
high-powered field (HPF). ∗∗∗ denotes 𝑝 < 0.005 compared to WT mice; 𝑛 = 6/group; 4 HPF/mouse. (d) Flow cytometric analysis of
foxp3+/CD3+ cells isolated from the LP of WT versus Nlrp3−/− mice on following 7 days of DSS exposure. ∗ denotes 𝑝 < 0.05 compared
to WT mice; 𝑛 = 6/group. (e) Flow cytometric analysis of IL-10 expression in foxp3+/CD4+ T regulatory cells isolated from the LP of WT
and Nlrp3−/−mice on day 7 of DSS. ∗∗∗ denotes 𝑝 < 0.005 compared to WT nice; 𝑛 = 5/group. (f) IL-17 expression in foxp3+/CD4+ cells
isolated from the LP of naive and DSS-treated WT and Nlrp3−/− mice. ∗ denotes 𝑝 < 0.05 compared to naive mice; # denotes 𝑝 < 0.05
compared to WT mice; 𝑛 = 6/group. (g) IL-17 expression in foxp3−/CD4+ cells isolated from the LP DSS-treated WT and Nlrp3−/− mice;
𝑛 = 6/group.
observed an increase in the number of IL-15 expressing
DCs isolated from the mesenteric lymph nodes (MLNs) of
Nlrp3−/− mice on day 7 of DSS (Figure 3(d)), without any
difference in mean fluorescence intensity (MFI; Figure 3(d)).
We also observed an increase in the number of IL-15 express-
ing lymphoid (LDC) and plasmacytoid (pDC) DCs isolated
from Nlrp3−/−mice on day 7 of DSS (Figure 3(f)) compared
toDCs isolated fromWTmice, without any difference inMFI
between strains (Figure 3(g)).
3.4. BM-Derived DCs from Nlrp3−/− Mice Exhibit Enhanced
Frequency of IL-15 Expression. Following our observation
that DCs isolated from the colonic LP and MLNs of DSS-
treated Nlrp3−/− mice displayed increased IL-15 surface
expression, we sought to determine if this was a property
intrinsic to the cells themselves, independent of their envi-
ronment.Thus, we differentiated BM-derived progenitor cells
isolated fromWT and Nlrp3−/−mice into DCs by culturing
them for 10 days in the presence of Flt3 ligand (Flt3L;
100 ng/mL). Indeed, a greater number of DCs generated from
BM isolated from Nlrp3−/− mice displayed IL-15 surface
expression when compared to cells differentiated from WT
BM (Figure 4(a)), an effect that was not associated with
an increase in IL-15-MFI (Figure 4(b)). To determine if
the differences in IL-15 expression were due to the loss of
inflammasome-dependent IL-1𝛽 production, we treated WT
and Nlrp3−/− DCs with exogenous IL-1𝛽 (100 ng/mL) in the
presence and absence of recombinant IL-1 receptor antagonist
(IL-1Ra; 100 𝜇g/mL). The number of WT DCs treated with
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Figure 3: Nlrp3−/−mice exhibit increased numbers of IL-15 expressing DCs in theMLN and colonic following a 7-day course of DSS. (a)The
quantification of IL-15 in colonic tissue isolated fromWT and Nlrp3−/− on day 7 of DSS. ∗ denote 𝑝 < 0.05 compared to WT; 𝑛 = 5/group.
Representative images of (b) WT and (c) Nlrp3−/− colonic sections stained for IL-15; scale bar = 100 microns. Flow cytometric analysis of
IL-15 expression on the surface of all DCs isolated from the MLNs of WT and Nlrp3−/− on day 7 of DSS, expressed as a percentage of IL-15
expressing cells (d) and mean fluorescence intensity (MFI) per cell (e); ∗ denotes 𝑝 < 0.05 compared to WT; 𝑛 = 6/group. Flow cytometric
analysis of IL-15 expression on the surface of lymphoid (CD11c+/CD8+; LDC) and plasmacytoid (CD11b+/B220+/CD11c−; pDC)DCs isolated
from the LP ofWT and Nlrp3−/−mice on day 7 of DSS, expressed as a percentage of IL-15 expressing cells (f) andMFI per cell (g); ∗ denotes
𝑝 < 0.05 compared to WT; 𝑛 = 5/group.
IL-1𝛽 displaying IL-15 expression was significantly reduced
(compared to the vehicle control, NoRx), an effect that was
blockedwith coincubationwith IL-1Ra. In contrast,Nlrp3−/−
DCs exhibited no significant changes in response to any of the
treatment conditions (Figure 4(c)).
3.5. Neutralizing IL-15 Protects Nlrp3−/− from Intestinal
Inflammation and Damage in the DSS Model of Colitis, an
Effect That Is Associated with Reduced Colonic IL-17. To
further assess the role of IL-15 in the increased suscepti-
bility of Nlrp3−/− to DSS-induced colitis, we employed an
antibody-based neutralization strategy. Nlrp3−/− mice were
treated with either a neutralizing anti-IL-15 antibody or an
IgG isotype control antibody at an equimolar dose (5𝜇g of
antibody/mouse/day). The neutralizing anti-IL-15 antibody
significantly reduced the severity of intestinal inflammation
induced by DSS in Nlrp3−/− mice as indicated by attenu-
ated body weight loss, reduced colonic inflammation, and
tissue damage (Figures 5(a)–5(c)) and a reduction in colonic
tissue MPO (Figure 5(d)), compared to isotype control-
treated Nlrp3−/− mice. Furthermore, neutralization of IL-
15 significantly reduced the number of foxp3+ cells detected
in colonic sections from Nlrp3−/− mice treated with DSS
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Figure 4: BM-derived DCs from Nlrp3−/− mice exhibit increased frequency of IL-15 expression an effect that cannot be normalized by
exogenous IL-1𝛽. (a) Flow cytometric analysis of IL-15 expression on the surface ofWT andNlrp3−/−DCs differentiated fromBMprogenitor
cells for 10 dayswith Flt3L (100 ng/mL), expressed as a percentage of IL-15 expressing cells (a) andMFI per cell (b). (c) Flow cytometric analysis
of IL-15 surface expression onWT and Nlrp3−/−DCs differentiated from BM progenitor cells for 10 days with Flt3L (100 ng/mL) and treated
with IL-1𝛽 (100 ng/mL) and/or recombinant IL-1 receptor antagonist (IL-1Ra; 100𝜇g/mL) for 12 hours. ∗ denotes 𝑝 < 0.05 compared to WT
mice; # denotes 𝑝 < 0.05 compared to WT, NoRx; $ denotes 𝑝 < 0.05 compared to WT-IL-1𝛽; 𝑛 = 5/group.
(Figure 5(e)). Lastly, while having no effect on colonic IL-
10 (Figure 5(f)), neutralization of IL-15 significantly reduced
the expression of IL-12p40 and IL-17 in colonic tissue isolated
fromNlrp3−/− on day 7 of DSS compared to isotype control-
treated Nlrp3−/−mice.
4. Discussion
In the current study, we have continued our assessment of
the role of the NLRP3 inflammasome in the regulation of
intestinal homeostasis. Herein, we describe how the loss of
NLRP3 signaling results in the increased expression of IL-15,
an inflammatory cytokine not previously associated with the
inflammasome, and changes in T cell phenotypes.
Alterations in the innate immune systemhave been impli-
cated in the pathogenesis of IBD, especially CD [2]. Studies
have reported thatmutations inNLRP3 are associatedwith an
increased risk for developing CD [3, 4]. We and others have
reported previously a protective role of the NLRP3 inflam-
masome in the maintenance of intestinal homeostasis in the
context of experimental colitis [6–8, 33]. However, whether
the loss of NLRP3 inflammasome function within the intesti-
nal epithelium or mucosal immune cells contributes to the
increased susceptibility to colitis is still a subject of debate.
Dupaul-Chicoine et al. concluded that the loss of NLRP3
inflammasome signaling, through the deletion of caspase-1 or
the adaptor protein ASC, resulted in enhanced sensitivity to
DSS-induced colitis [33]. Furthermore, caspase-12−/− mice,
which exhibit increased NLRP3 inflammasome signaling,
were protected from DSS-induced colitis [33]. The increased
sensitivity of caspase-1−/−mice toDSSwas nearly completely
reversed upon administration of recombinant IL-18, but only
partially reversed upon adoptive transfer ofWTmyeloid cells,
suggesting that a loss of inflammasome signaling in non-
myeloid cells was responsible for the enhanced sensitivity to
DSS-induced colitis [33]. Similarly, Zaki et al. reported that
deletion of NLRP3, caspase-1 or ASC, increased sensitivity to
DSS-induced colitis [34], an effect that could be completely
reversed by administration of recombinant IL-18. As reported
by Dupaul-Chicoine et al., the loss of inflammasome sig-
naling within the nonhematopoietic compartment conferred
the susceptibility [34]. Interestingly, Zaki et al. were able to
demonstrate that IL-18 production from colonic intestinal
epithelial cells was increased following the induction of colitis
inWT, but not ASC–/– or caspase-1–/–mice [34]. In contrast
to the aforementioned studies, chimeric experiments per-
formed by Allen et al. revealed that the loss of NLRP3 in
BM-derived cells enhanced susceptibility to DSS inNlrp3−/−
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Figure 5: A neutralizing anti-IL-15 antibody normalizes the sensitivity of Nlrp3−/− mice to DSS and reduces colonic IL-17 expression. (a)
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(b) Representative hematoxylin and eosin stained colonic sections (scale bar = 100 microns) and (c) blind assessment of tissue damage and
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of IL-10, IL-12p40, and IL-17 in colonic tissue isolated from Nlrp3−/−mice treated with an IgG isotype (iso) control antibody and Nlrp3−/−
mice treated with a neutralizing anti-IL-15 (𝛼-IL-15) antibody on day 7 of DSS. ∗ denotes 𝑝 < 0.05 compared to Nlrp3−/−mice treated with
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mice [8]. They reported that both WT and Nlrp3−/− mice
receiving Nlrp3−/− bone marrow exhibited enhanced weight
loss, increased severity of disease, and elevated histological
assessment scores, compared to WT recipient mice [8].
In our previous report, we found that NLRP3 deficiency
altered the expression of intestinal epithelial cell-derived
antimicrobial peptides, an effect that reduced bacterial killing
and was associated with a distinct fecal microbiota profile
[6], suggesting that inflammasome signaling within the
nonhematopoietic cell compartment may be contributing to
the increased susceptibility to DSS-induced colitis. However,
in the current study, we found that that NLRP3-deficiency
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was associated with elevated expression of IL-15 on the
surface of DCs, an effect that was associated with increased
expression of IL-17 in foxp3+ T cells. Interestingly, our
immunofluorescence assessment of DSS-exposed Nlrp3−/−
mice revealed IL-15 expression in mucosal immune cells, but
little expression in the intestinal epithelium. Furthermore,
neutralizing IL-15 normalized the susceptibility of Nlrp3−/−
mice toDSS-induced colitis, an effect that was associatedwith
reduced expression of IL-17 in colonic tissues. Taken together,
our data suggest that the loss of inflammasome signaling in
myeloid cells may contribute to the increased sensitivity to
DSS-induced colitis seen in Nlrp3−/−mice.
In the gastrointestinal tract, IL-15 is primarily expressed
by DCs and epithelial cells and can regulate the proliferation
and function of a variety of immune cells through stimulation
of neighboring cells via trans-presentation [35, 36]. Studies
assessing the mechanisms governing the production of IL-
15 have revealed that its expression as a functional protein
is regulated at the translational level; however, very little
is known about the signals and the mechanisms that drive
its expression on the cell surface [35, 36]. In our study,
DSS-treated Nlrp3−/− mice exhibited significant increases
in colonic tissue levels of IL-15. Immunostaining revealed
increased IL-15 expression in the cells of the LP and sub-
mucosal compartment, with limited positive staining on the
epithelial layer. Further assessment of LP cells isolated from
Nlrp3−/−mice revealed that DCs exhibited enhanced surface
expression of IL-15. Currently there is no documented link
between the NLRP3 inflammasome and the regulation of IL-
15 expression. However, acetaminophen-induced liver injury
is mediated by the activation of the NLRP3 inflammasome
and subsequent production of IL-1𝛽 [37, 38], whereas the
expression of IL-15 is protective in this system [39], suggesting
a reciprocal relationship between NLRP3 and IL-15 in this
response. In our study, we observed a similar reciprocal
relationship between NLRP3 and IL-15, where the expression
of NLRP3 protects mice from experimental colitis and its
deletion leads to increased IL-15 expression and enhanced
intestinal inflammation. In our in vitro experiments, exoge-
nous IL-1𝛽 could reduce the expression of IL-15 in WT DCs
but had no effect onNlrp3−/−DCs.These data are perplexing
and suggest that NLRP3 may play a role in the response to
cytokines and the downstream regulation of IL-15 expression.
Recently it was reported that NLRP3 can regulate intracel-
lular signaling in an inflammasome-independent fashion,
suggesting NLR proteins may elicit biological responses
through mechanisms beyond their downstream activation
of caspase-1 [40]. In this report, TGF-𝛽-induced SMAD2/3
phosphorylation was attenuated in NLRP3-deficient cells, an
effect that was independent of IL-1𝛽, IL-18, caspase-1, or the
inflammasome adaptor ASC [40]. Since very little is known
about the regulation of IL-15 expression and trafficking to the
membrane, future studies will be required to determine how
NLRP3 might interact with these processes, independent of
its role in inflammasome signaling.
Functionally, IL-15 has been implicated in the pathogen-
esis of chronic inflammatory disorders including psoriasis,
rheumatoid arthritis, and celiac disease [36]. IL-15 has also
been implicated in the pathogenesis of IBD, as mucosal
mononuclear cells from IBD patients express increased levels
of IL-15, and serum IL-15 levels are increased in patients with
IBD [41]. Expression of IL-15 transcripts has also been found
to be elevated in the inflamed rectal mucosa of IBD patients
[41]. Interestingly, Bouchaud et al. reported that the response
to anti-TNF (infliximab) in CD patients was associated with
a significant decrease in serum levels of IL-15 [42].
In addition to regulating cells of the innate immune sys-
tem, IL-15 has been reported to inhibit the regulatory capacity
of Tregs and induce the polarization of T cells to a Th17
phenotype [22, 23]. IL-15 can drive CD25High foxp3+ cells to
become IL-17-secreting cells, an effect that is not modulated
by IL-6 or TGF-𝛽 [23]. In the context of rheumatoid arthritis,
IL-15 drives the development and proliferation of Th17 cells
in a mechanism that may involve IL-12 as an intermediary
[22]. In our in vivo studies, neutralization of IL-15 reduced
the expression of IL-12p40, the subunit shared by IL-12 and
IL-23 [43], in colonic tissues, a response that was associated
with normalization of foxp3+ cell numbers and reduced IL-
17 expression, suggesting that either IL-12 or IL-23 signaling
mediates these responses. In support of this, Depaolo et al.
reported that aberrant IL-15 expression in conjunction with
retinoic acid can “break” tolerance to dietary luminal anti-
gens through IL-12/23-dependent inhibition of Treg function
and the initiation ofTh1- andTh17-like responses [30]. Taken
together these data suggest that IL-15 may be contributing to
the loss in the regulatory, or tolerance, capacity within the
mucosal immune system of colitic Nlrp3−/− mice through
an IL-12/23-dependent mechanism.
In our in vivo studies, we observed that the loss of
NLRP3 increased a population of foxp3+T cells that exhibited
enhanced expression of IL-17. In humans, Hovhannisyan et
al. reported the existence of a subset of CD4+ cells in the
inflamed mucosa of CD patients that shared the phenotype
of Th17 and Treg cells. These cells that express both foxp3
and IL-17 were hypothesized to arise during the differenti-
ation of Th17 and Treg cells [27]. We have also previously
demonstrated that the prevalence of circulating IL-17 and
foxp3 double expressing cells is associatedwith impaired Treg
function, suggesting the increased Treg plasticity towards
Th17 in IBD patients [28]. In our current study, increased IL-
15 expression inNlrp3−/−micewas associatedwith increased
numbers ofmucosal foxp3+ cells following 7 days of DSS.The
foxp3+ T cells isolated from colitic Nlrp3−/−mice expressed
significantly less intracellular IL-10 but exhibited enhanced
IL-17 expression. Interestingly, the proliferation of foxp3+
cells and the increased colonic tissue expression of IL-17 were
reversed when IL-15 was neutralized during DSS exposure.
The role of IL-15 in animal models of intestinal inflam-
mation is controversial. Yoshihara et al. reported that IL-15-
deficient mice exhibited resistance to DSS-induced intestinal
injury [44]. Furthermore, inhibition of IL-15 signaling, via
antibody-mediated blockade of the IL-15 receptor, protected
IL-15-overexpressing mice from intestinal damage [45]. In
contrast, Obermeier et al. reported neutralization of IL-15
with soluble IL-15 receptor-𝛼 (IL-15R𝛼) aggravated intestinal
epithelial tissue damage and increased the expression of
colonic IFN𝛾 and TNF-𝛼 in the DSS model of colitis [46].
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However, the use of soluble IL-15R𝛼 to inhibit IL-15 activity
remains controversial. Reports suggest that the soluble IL-
15R𝛼 can enhance rather than inhibit IL-15 binding and activ-
ity through the IL-2/IL-15R𝛽𝛾 subunits [47]. Furthermore,
others have reported that the soluble IL-15R𝛼 can prolong
the signaling life of IL-15 and enhance its ability to signal
through a pseudo-trans-presentationmechanism [47]. In our
study, attenuation of IL-15 signaling with anti-IL-15 antibody
treatment was protective, suggesting the method used to
inhibit blockade of IL-15 signaling may be important when
studying its role in vivo.
In summary, we have shown that the increased sensitivity
of Nlrp3−/− mice to DSS-induced colitis can be normalized
by neutralizing IL-15, an effect that decreases the number of
mucosal foxp3+ T cells and significantly reduces the colonic
expression of IL-12p40 and IL-17. These data suggest that the
NLRP3 inflammasome can regulate intestinal inflammation
through noncanonical mechanisms, providing additional
insight as to how hypofunctional mutations in NLRP3 may
contribute to the pathogenesis of IBD.
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